Verteporfin 15mg powder for solution for infusion vials
Requires a prescription from a doctor or prescriber
Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative comprising a 50:50 mixture of two isomers: [CL-315555] and [CL-315585].
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Verteporfin
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Verteporfin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Verteporfin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Verteporfin on the MHRA register
Verteporfin 15mg powder for solution for infusion vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Aflibercept for treating choroidal neovascularisation (TA486)
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 8 · Randomised trials: 14 · 1996–2025
Showing the 50 most relevant studies, sorted by most relevant.
Adrian Koh, Timothy Y. Y. Lai, Kanji Takahashi, et al.
JAMA Ophthalmology, 2017
- Ranibizumab
- Verteporfin
- Choroid
Tock Han Lim, Timothy Y. Y. Lai, Kanji Takahashi, et al.
JAMA Ophthalmology, 2020
- Ranibizumab
- Verteporfin
- Choroid
Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group
Archives of Ophthalmology, 1999
- Photochemotherapy
- Verteporfin
- Fluorescein Angiography
American Journal of Ophthalmology, 2001
- Photochemotherapy
- Verteporfin
- Blindness
VERTEPORFIN ROUNDTABLE 2000 AND 2001 PARTICIPANTS, TREATMENT OF AGE-RELATED MACULAR DEGENERATION WITH PHOTODYNAMIC THERAPY (TAP) STUDY GROUP PRINCIPAL INVESTIGATORS, AND VERTEPORFIN IN PHOTODYNAMIC THERAPY (VIP) STUDY GROUP PRINCIPAL INVESTIGATORS
Retina, 2002
- Photochemotherapy
- Verteporfin
- Fluorescein Angiography
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups
Archives of Ophthalmology, 2003
- Photochemotherapy
- Verteporfin
- Fluorescein Angiography
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group
Archives of Ophthalmology, 2002
- Photochemotherapy
- Verteporfin
- Choroid
Visudyne in Minimally Classic Choroidal Neovascularization Study Group*
Archives of Ophthalmology, 2005
- Photochemotherapy
- Verteporfin
- Fluorescein Angiography
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy(TAP) Study Group
Archives of Ophthalmology, 2002
- Photochemotherapy
- Verteporfin
- Fluorescein Angiography
Alan F. Cruess, Gergana Zlateva, Andreas M. Pleil, et al.
Acta Ophthalmologica, 2008
- Photochemotherapy
- Verteporfin
- Cost-Benefit Analysis
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
5-6 hours
Mechanism
Verteporfin is transported in the plasma primarily by lipoproteins.
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
5-6 hours
Metabolism
Elimination
0.01%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 39 of 39 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins that carry this drug through the body
Lp(a) may be a ligand for megalin/Gp 330
ATC S01LA01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Verteporfin
Additional database identifiers
Drugs Product Database (DPD)
11996
ChemSpider
4515032
HUGO Gene Nomenclature Committee (HGNC)
HGNC:600
GenAtlas
APOA1
GeneCards
APOA1
GenBank Gene Database
BC110286
UniProt Accession
APOA1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:601
GenAtlas
APOA2
GeneCards
APOA2
GenBank Gene Database
X00955
GenBank Protein Database
28748
UniProt Accession
APOA2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:602
GeneCards
APOA4
UniProt Accession
APOA4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:603
GeneCards
APOB
UniProt Accession
APOB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:609
GeneCards
APOC2
UniProt Accession
APOC2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:610
GeneCards
APOC3
UniProt Accession
APOC3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:612
GeneCards
APOD
UniProt Accession
APOD_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:613
GenAtlas
APOE
GeneCards
APOE
GenBank Gene Database
M12529
GenBank Protein Database
178849
UniProt Accession
APOE_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:618
GeneCards
APOL1
UniProt Accession
APOL1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:13916
GeneCards
APOM
GenBank Gene Database
AF118393
GenBank Protein Database
6289103
UniProt Accession
APOM_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6667
GenAtlas
LPA
GeneCards
LPA
GenBank Gene Database
X06290
GenBank Protein Database
28620
UniProt Accession
APOA_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72